MSers on trials risk a lot to potentially gain, but they sometimes lose, but they are the people that allow drugs to become licenced so that companies can make money. These people need proper provision for access to drugs should they need retreating. It is great news some people can continue a treatment which obviously does some good. However the question is who are the few neuros and what about the MSers who got the drug off–label treated by other neuros that are not on the select list? Will they get access, maybe after referral to one of the few neuros who will have access to the drug. At least this way the consistency of monitoring can be ensured. The company got the cash for the cost of the drug for the off-label use, should they not stick by the MSer until Lemtrada gets approved?